COSCIENS Biopharma Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Anna Biehn

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	3.8yrs
Yönetim Kurulu ortalama görev süresi	less than a year

Son yönetim güncellemeleri

Recent updates

We're Hopeful That Aeterna Zentaris (TSE:AEZS) Will Use Its Cash Wisely

May 10

We're Interested To See How Aeterna Zentaris (TSE:AEZS) Uses Its Cash Hoard To Grow

Nov 12

Here's Why We're Not At All Concerned With Aeterna Zentaris' (TSE:AEZS) Cash Burn Situation

Jul 15

Companies Like Aeterna Zentaris (TSE:AEZS) Can Afford To Invest In Growth

Mar 29

Reflecting on Aeterna Zentaris' (TSE:AEZS) Share Price Returns Over The Last Five Years

Feb 04

CEO

Anna Biehn

less than a year

Görev süresi

Mrs. Anna Elizabeth Biehn served as the Chairperson of the Board at Agro Tech Foods Limited from July 17, 2014 to December 30, 2016. Mrs. Biehn served as the President, Consumer Foods International joined...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Giuliano La Fratta	Senior VP of Finance & CFO	3.8yrs	US$465.51k	Veri yok
Michel Regnier	Senior VP of Technical operations	no data	US$213.98k	Veri yok
Michael Teifel	Senior Vice President of GmbH & Chief Scientific Officer	4.4yrs	US$217.44k	Veri yok
Matthias Gerlach	Senior Vice President Manufacturing and Supply Chain & Head of Production	no data	US$259.50k	Veri yok
Anna Biehn	Chief Executive Officer	less than a year	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: CSCI 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Daniel Von Hoff	Member of the Scientific Advisory Board	19.9yrs	Veri yok	Veri yok
Gerald Batist	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Hartmut Michel	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Marcel Verheij	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Rene De Frydman	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Alan DeCherney	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Klaus H. Diedrich	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Frans M. Debruyne	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Ulf Rapp	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Peter Puccetti	Independent Chairman	less than a year	Veri yok	0.49% CA$ 58.2k
Robert Seager	Independent Director	less than a year	Veri yok	Veri yok
David Spear	Independent Director	less than a year	Veri yok	Veri yok

0.4yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: CSCI 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 0.4 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/10/06 21:36
Gün Sonu Hisse Fiyatı	2025/10/06 00:00
Kazançlar	2025/06/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

COSCIENS Biopharma Inc. 16 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Douglas Loe	Byron Capital Markets
Douglas Loe	Cantor Fitzgerald Canada Corporation
Charles Duncan	Citizens JMP Securities, LLC

COSCIENS Biopharma Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

COSCIENS Biopharma Inc., Annual General Meeting, Jun 26, 2025

COSCIENS Biopharma Inc. Announces Chief Executive Officer Changes

COSCIENS Biopharma Inc. Announces Resignation of Carolyn Egbert from the Board of Directors

Cosciens Biopharma Inc. Announces Directorate Changes

Aeterna Zentaris Inc. Announces the Resignation of Peter G. Edwards as Director

Aeterna Zentaris Inc., Annual General Meeting, Jul 02, 2024

Recent updates

COSCIENS Biopharma Inc.(OTCPK:CSCI.F) dropped from NASDAQ Composite Index

Second quarter 2025 earnings released: US$0.85 loss per share (vs US$0.64 loss in 2Q 2024)

First quarter 2025 earnings released: US$1.16 loss per share (vs US$0.76 loss in 1Q 2024)

COSCIENS Biopharma Inc., Annual General Meeting, Jun 26, 2025

COSCIENS Biopharma Inc. Announces Chief Executive Officer Changes

New major risk - Financial position

Full year 2024 earnings released: US$5.93 loss per share (vs US$13.64 loss in FY 2023)

New major risk - Market cap size

COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product

New major risk - Market cap size

Third quarter 2024 earnings released: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023)

COSCIENS Biopharma Inc. Announces Resignation of Carolyn Egbert from the Board of Directors

Cosciens Biopharma Inc. Announces Directorate Changes

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT- Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Second quarter 2024 earnings released: US$0.64 loss per share (vs US$2.07 loss in 2Q 2023)

Aeterna Zentaris Inc. Announces the Resignation of Peter G. Edwards as Director

Aeterna Zentaris Inc. (TSX:AEZS) completed the acquisition of Ceapro Inc. (TSX:AEZS) in a merger of equals transaction.

Aeterna Zentaris Inc., Annual General Meeting, Jul 02, 2024

Aeterna Zentaris Inc. (TSX:AEZS) entered into a definitive agreement to acquire Ceapro Inc. (TSXV:CZO) for CAD 21.4 million in a merger of equals.

Aeterna Zentaris Inc. Provides an Update on Its Therapeutic and Diagnostic Development Pipeline Programs and Outlined Upcoming Key Milestones

Aeterna Zentaris Announces Effective Date of Share Consolidation

Aeterna Zentaris Inc., Annual General Meeting, Jul 15, 2022

Aeterna Zentaris Inc., Annual General Meeting, Jul 06, 2022

Aeterna Zentaris Inc. Achieves Proof-Of-Concept for the Treatment of NMOSD with AIM Biologicals Program

Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (Macimorelin) for Diagnosing Adult Growth Hormone Deficiency

Aeterna Zentaris Inc. Updates on Positive Pre-Clinical Results from Aim Biologicals Development Program for the Potential Treatment of Parkinson's Disease

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

We're Hopeful That Aeterna Zentaris (TSE:AEZS) Will Use Its Cash Wisely

Aeterna Zentaris Inc., Annual General Meeting, Jun 21, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Aeterna Zentaris Receives 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

We're Interested To See How Aeterna Zentaris (TSE:AEZS) Uses Its Cash Hoard To Grow

Third quarter 2021 earnings released: US$0.014 loss per share (vs US$0.02 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.017 loss per share (vs US$0.15 loss in 2Q 2020)

Aeterna Zentaris Inc. Provides Update on Its Pre-Clinical and Clinical Development Programs

Here's Why We're Not At All Concerned With Aeterna Zentaris' (TSE:AEZS) Cash Burn Situation

Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit

Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease)

Aeterna Zentaris Inc. Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Independent Director has left the company

Aeterna Zentaris Announces the Selection of A Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism

First quarter 2021 earnings released: US$0.015 loss per share (vs US$0.036 profit in 1Q 2020)

Companies Like Aeterna Zentaris (TSE:AEZS) Can Afford To Invest In Growth

Full year 2020 earnings released: US$0.13 loss per share (vs US$0.34 loss in FY 2019)

Aeterna Zentaris Inc., Annual General Meeting, May 05, 2021

New 90-day high: CA$1.37

Reflecting on Aeterna Zentaris' (TSE:AEZS) Share Price Returns Over The Last Five Years

Aeterna Zentaris Inc. Enters into an Exclusive Option Agreement to Evaluate Preclinical Potential COVID-19 Vaccine Developed at the Julius-Maximilians-University Wuerzburg

Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics

The Nasdaq Stock Market LLC Grants an Additional 180 Calendar-Day Period Extension to Aeterna Zentaris to Regain Compliance with Minimum Bid Price Rule

New 90-day high: CA$0.90

New 90-day high: CA$0.66

Aeterna Zentaris Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin

Aeterna Zentaris Inc. Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin

New 90-day low: CA$0.39

Third quarter 2020 earnings released: US$0.02 loss per share

New 90-day low: CA$0.46

The Rosen Law Firm, P.A. and Glancy Prongay & Murray LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Securities of Aeterna Zentaris, Inc

Aeterna Zentaris Inc. Announces Macimorelin Clinical Program Update

Aeterna Zentaris Inc. has completed a Follow-on Equity Offering in the amount of $7.000001 million.

Aeterna Receives Nasdaq Warning on Minimum Price

Aeterna Zentaris Inc. has completed a Composite Units Offering in the amount of $11.999087 million.

Aeterna Zentaris Inc.(NasdaqCM:AEZS) dropped from Russell Microcap Value Index

CEO

Liderlik Ekibi

Yönetim Kurulu Üyeleri

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları

Analiz Modeli ve Kar Tanesi